| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
Articles |
A study of the plasma pharmacokinetics, tumor localization, and safety of a single dose of doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol (PEG-liposomal doxorubicin) was conducted in patients with Kaposi's sarcoma (KS) as a manifestation of acquired immune deficiency syndrome (AIDS). Eighteen patients with AIDS-KS diagnosed by examination of biopsy specimens were randomly assigned to receive either standard doxorubicin or PEG-liposomal doxorubicin. Consecutive participants were entered at three dose levels (10, 20, and 40 mg/m2) in ascending fashion. Clearance of PEG-liposomal doxorubicin was 0.034 L/h/m2 to 0.108 L/h/m2, volume of distribution (Vd) was 2.2 L/m2 to 4.4 L/m2, and half-lives (t1/2) of the initial decline in the plasma concentration-time curve and of the terminal decline were 3.77 hours and 41.3 hours, respectively. Seventy-two hours after administration, doxorubicin levels observed in lesions of patients receiving PEG-liposomal doxorubicin were 5.2 to 11.4 times greater than those found in patients given comparable doses of standard doxorubicin. PEG-liposomal doxorubicin and standard doxorubicin were roughly equipotent in producing toxicity. Encapsulation in liposomes containing surface-bound PEG significantly limits the distribution and elimination of doxorubicin, results in greater accumulation of the drug in KS lesions 72 hours after dosing than does standard doxorubicin, and may improve drug efficacy and therapeutic index in the treatment of AIDS-KS.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Lo, C.-T. Lin, and H.-C. Wu Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery Mol. Cancer Ther., March 1, 2008; 7(3): 579 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, L. Yang, Z. Chen, and D. M. Shin Application of Nanotechnology in Cancer Therapy and Imaging CA Cancer J Clin, March 1, 2008; 58(2): 97 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system Mol. Cancer Ther., November 1, 2007; 6(11): 3019 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Skubitz and D. R. D'Adamo Sarcoma Mayo Clin. Proc., November 1, 2007; 82(11): 1409 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, A. Jacobs, J. Curtin, and F Muggia Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil(R)): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer Ann. Onc., April 1, 2007; 18(4): 716 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cooley, D. Henry, M. Tonda, S. Sun, M. O'Connell, and W. Rackoff A Randomized, Double-Blind Study of Pegylated Liposomal Doxorubicin for the Treatment of AIDS-Related Kaposi's Sarcoma Oncologist, January 1, 2007; 12(1): 114 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Kirpotin, D. C. Drummond, Y. Shao, M. R. Shalaby, K. Hong, U. B. Nielsen, J. D. Marks, C. C. Benz, and J. W. Park Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models. Cancer Res., July 1, 2006; 66(13): 6732 - 6740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Bedikian, A. Vardeleon, T. Smith, S. Campbell, and R. Namdari Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. J. Clin. Pharmacol., July 1, 2006; 46(7): 727 - 737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Laginha, S. Verwoert, G. J.R. Charrois, and T. M. Allen Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors Clin. Cancer Res., October 1, 2005; 11(19): 6944 - 6949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mirchandani, H. Hochster, A. Hamilton, L. Liebes, H. Yee, J. P. Curtin, S. Lee, J. Sorich, C. Dellenbaugh, and F. M. Muggia Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5912 - 5919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Allen, D. R. Mumbengegwi, and G. J.R. Charrois Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates Clin. Cancer Res., May 1, 2005; 11(9): 3567 - 3573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Allen and P. R. Cullis Drug Delivery Systems: Entering the Mainstream Science, March 19, 2004; 303(5665): 1818 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E. H. Moase, T. M. Allen, and M. Ponzoni Doxorubicin-loaded Fab' Fragments of Anti-disialoganglioside Immunoliposomes Selectively Inhibit the Growth and Dissemination of Human Neuroblastoma in Nude Mice Cancer Res., January 1, 2003; 63(1): 86 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hamilton, L. Biganzoli, R. Coleman, L. Mauriac, P. Hennebert, A. Awada, M. Nooij, L. Beex, M. Piccart, I. Van Hoorebeeck, et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx(R), Doxil(R)) at a 6-week interval in patients with metastatic breast cancer Ann. Onc., June 1, 2002; 13(6): 910 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. Kouloulias, C. E. Dardoufas, J. R. Kouvaris, C. S. Gennatas, A. K. Polyzos, H. J. Gogas, P. H. Sandilos, N. K. Uzunoglu, E. G. Malas, and L. J. Vlahos Liposomal Doxorubicin in Conjunction with Reirradiation and Local Hyperthermia Treatment in Recurrent Breast Cancer: A Phase I/II Trial Clin. Cancer Res., February 1, 2002; 8(2): 374 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Banerjee Liposomes: Applications in Medicine J Biomater Appl, July 1, 2001; 16(1): 3 - 21. [Abstract] [PDF]
|
|
|
|
 |
|
 S. M. Moghimi, A. C. Hunter, and J. C. Murray Long-Circulating and Target-Specific Nanoparticles: Theory to Practice Pharmacol. Rev., June 1, 2001; 53(2): 283 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. P. Medina, T. Söderlund, L. J. Laakkonen, E. K. J. Tuominen, E. Koivunen, and P. K. J. Kinnunen Binding of Novel Peptide Inhibitors of Type IV Collagenases to Phospholipid Membranes and Use in Liposome Targeting to Tumor Cells in Vitro Cancer Res., May 1, 2001; 61(10): 3978 - 3985. [Abstract] [Full Text]
|
|
|
|
|
|
K. J. Harrington, G. Rowlinson-Busza, K. N. Syrigos, R. G. Vile, P. S. Uster, A. M. Peters, and J. S. W. Stewart Pegylated Liposome-encapsulated Doxorubicin and Cisplatin Enhance the Effect of Radiotherapy in a Tumor Xenograft Model Clin. Cancer Res., December 1, 2000; 6(12): 4939 - 4949. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Kassner Evaluation and Treatment of Chemotherapy Extravasation Injuries Journal of Pediatric Oncology Nursing, July 1, 2000; 17(3): 135 - 148. [Abstract] [PDF]
|
|
|
|
|
|
D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Working, M. S. Newman, T. Sullivan, and J. Yarrington Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 1128 - 1133. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Fielding, L. Moon-Mcdermott, R. O. Lewis, and M. J. Horner Pharmacokinetics and Urinary Excretion of Amikacin in Low-Clearance Unilamellar Liposomes after a Single or Repeated Intravenous Administration in the Rhesus Monkey Antimicrob. Agents Chemother., March 1, 1999; 43(3): 503 - 509. [Abstract] [Full Text]
|
|
|
|
 |
|
 M Amantea, M S Newman, T M Sullivan, A Forrest, and P K Working Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs Human and Experimental Toxicology, January 1, 1999; 18(1): 17 - 26. [Abstract] [PDF]
|
|
|
|
|
|
F. M. Muggia Doxorubicin-Polymer Conjugates: Further Demonstration of the Concept of Enhanced Permeability and Retention Clin. Cancer Res., January 1, 1999; 5(1): 7 - 8. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
